AR039358A1 - Formulacion liquida que comprende cetuximab. - Google Patents
Formulacion liquida que comprende cetuximab.Info
- Publication number
- AR039358A1 AR039358A1 ARP020102605A ARP020102605A AR039358A1 AR 039358 A1 AR039358 A1 AR 039358A1 AR P020102605 A ARP020102605 A AR P020102605A AR P020102605 A ARP020102605 A AR P020102605A AR 039358 A1 AR039358 A1 AR 039358A1
- Authority
- AR
- Argentina
- Prior art keywords
- cetuximab
- cancer cells
- egf receptor
- liquid formulation
- receptor
- Prior art date
Links
- 229960005395 cetuximab Drugs 0.000 title abstract 4
- 239000012669 liquid formulation Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 102000001301 EGF receptor Human genes 0.000 abstract 3
- 108060006698 EGF receptor Proteins 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 2
- 229920001214 Polysorbate 60 Polymers 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 238000011254 conventional chemotherapy Methods 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- -1 fatty acid ester Chemical class 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000008363 phosphate buffer Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una formulación farmacéutica líquida que comprende Cetuximab, un buffer fosfato con un pH entre 6 y 8, y un éster de ácido graso de polioxietilen sorbitán. El Cetuximb es un anticuerpo monoclonal quimérico contra el receptor del factor de crecimiento epidérmico (receptor EGF). El bloqueo del receptor EGF por anticuerpos tales como el Cetuximab actúa contra los tumores en varios planos, p. ej. inhibiendo la proliferación de células cancerígenas, reduciendo la angiogénesis mediada por tumores, induciendo la apoptosis de las células cancerígenas e incrementando los efectos tóxicos de la radioterapia y la quimioterapia convencional. Esta formulación líquida que contiene Cetuximab es adecuada para la administración parenteral, se tolera bien y es estable durante un almacenamiento de al menos un ano a temperatura ambiente. Además, tiene una composición simple y no comprende sustancias auxiliares cuestionables desde el punto de vista toxicológico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10133394A DE10133394A1 (de) | 2001-07-13 | 2001-07-13 | Flüssige Formulierung enthaltend Cetuximab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039358A1 true AR039358A1 (es) | 2005-02-16 |
Family
ID=7691220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102605A AR039358A1 (es) | 2001-07-13 | 2002-07-12 | Formulacion liquida que comprende cetuximab. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20040170632A1 (es) |
| EP (1) | EP1406658A1 (es) |
| JP (1) | JP2004536129A (es) |
| KR (1) | KR20040018458A (es) |
| CN (1) | CN1231264C (es) |
| AR (1) | AR039358A1 (es) |
| BR (1) | BR0211060A (es) |
| CA (1) | CA2453342A1 (es) |
| CZ (1) | CZ2004189A3 (es) |
| DE (1) | DE10133394A1 (es) |
| HU (1) | HUP0401046A3 (es) |
| MX (1) | MXPA04000340A (es) |
| PE (1) | PE20030433A1 (es) |
| PL (1) | PL364599A1 (es) |
| RU (1) | RU2004102395A (es) |
| SK (1) | SK862004A3 (es) |
| WO (1) | WO2003007988A1 (es) |
| ZA (1) | ZA200401161B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200506159B (en) | 2003-02-10 | 2006-10-25 | Elan Pharm Inc | Immunoglobulin formulation and method of preparation thereof |
| DE10355251A1 (de) * | 2003-11-26 | 2005-06-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor |
| DE10355904A1 (de) * | 2003-11-29 | 2005-06-30 | Merck Patent Gmbh | Feste Formen von anti-EGFR-Antikörpern |
| EP1713502A1 (de) * | 2004-02-12 | 2006-10-25 | MERCK PATENT GmbH | Hochkonzentrierte, flüssige formulierungen von anti-egfr-antikörpern |
| NZ550430A (en) * | 2004-04-27 | 2009-06-26 | Wellstat Biologics Corp | Cancer treatment using viruses and camptothecins |
| JP2008519757A (ja) * | 2004-11-12 | 2008-06-12 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 抗ｅｇｆｒ抗体の固形物 |
| US20090047278A1 (en) * | 2005-02-28 | 2009-02-19 | Eisai R & D Management Co., Ltd. | Novel Combinational Use of Sulfonamide Compound |
| TW200800181A (en) | 2006-02-09 | 2008-01-01 | Sankyo Co | Pharmaceutical composition for anticancer |
| WO2007128557A1 (en) | 2006-05-03 | 2007-11-15 | Bayer Schering Pharma Aktiengesellschaft | Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody |
| PE20081179A1 (es) * | 2006-10-06 | 2008-09-29 | Amgen Inc | Formulaciones estables de anticuerpos egfr |
| CA2666492C (en) * | 2006-10-20 | 2012-07-17 | Douglas Rehder | Stable polypeptide formulations |
| CN107773755B (zh) * | 2016-08-31 | 2021-06-22 | 上海津曼特生物科技有限公司 | 抗表皮生长因子受体单克隆抗体的注射液制剂 |
| EP3624846B1 (en) | 2017-05-16 | 2024-08-07 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity including a combination of nicotinic acid and tryoptophan |
| WO2020004368A1 (ja) * | 2018-06-25 | 2020-01-02 | Ｊｃｒファーマ株式会社 | 蛋白質含有水性液剤 |
| CA3110860A1 (en) * | 2018-08-31 | 2020-03-05 | Amplyx Pharmaceuticals, Inc. | Compounds and methods for treating fungal infections |
| CN120239616A (zh) * | 2023-11-29 | 2025-07-01 | 四川科伦博泰生物医药股份有限公司 | 抗体制剂 |
| WO2025245256A1 (en) | 2024-05-22 | 2025-11-27 | Tizona Therapeutics, Inc. | Combination therapy involving anti-hla-g antibodies and anti- egfr antibodies or anti-pd-1 antibodies |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4128089A (en) * | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US5945098A (en) * | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
| AU6267896A (en) * | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| MX9800684A (es) * | 1995-07-27 | 1998-04-30 | Genentech Inc | Formulacion de proteinas liofilizadas isotonicas estables. |
-
2001
- 2001-07-13 DE DE10133394A patent/DE10133394A1/de not_active Withdrawn
-
2002
- 2002-06-18 CA CA002453342A patent/CA2453342A1/en not_active Abandoned
- 2002-06-18 CZ CZ2004189A patent/CZ2004189A3/cs unknown
- 2002-06-18 CN CNB028141059A patent/CN1231264C/zh not_active Expired - Fee Related
- 2002-06-18 HU HU0401046A patent/HUP0401046A3/hu unknown
- 2002-06-18 EP EP02751038A patent/EP1406658A1/de not_active Withdrawn
- 2002-06-18 KR KR10-2004-7000530A patent/KR20040018458A/ko not_active Withdrawn
- 2002-06-18 PL PL02364599A patent/PL364599A1/xx unknown
- 2002-06-18 RU RU2004102395/15A patent/RU2004102395A/ru not_active Application Discontinuation
- 2002-06-18 BR BR0211060-1A patent/BR0211060A/pt not_active IP Right Cessation
- 2002-06-18 MX MXPA04000340A patent/MXPA04000340A/es unknown
- 2002-06-18 WO PCT/EP2002/006696 patent/WO2003007988A1/de not_active Ceased
- 2002-06-18 JP JP2003513593A patent/JP2004536129A/ja not_active Withdrawn
- 2002-06-18 US US10/483,404 patent/US20040170632A1/en not_active Abandoned
- 2002-06-18 SK SK86-2004A patent/SK862004A3/sk not_active Application Discontinuation
- 2002-07-11 PE PE2002000618A patent/PE20030433A1/es not_active Application Discontinuation
- 2002-07-12 AR ARP020102605A patent/AR039358A1/es unknown
-
2004
- 2004-02-12 ZA ZA200401161A patent/ZA200401161B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003007988A1 (de) | 2003-01-30 |
| MXPA04000340A (es) | 2004-05-04 |
| PE20030433A1 (es) | 2003-05-24 |
| SK862004A3 (en) | 2004-07-07 |
| BR0211060A (pt) | 2004-07-20 |
| JP2004536129A (ja) | 2004-12-02 |
| CZ2004189A3 (cs) | 2004-05-12 |
| EP1406658A1 (de) | 2004-04-14 |
| CN1527724A (zh) | 2004-09-08 |
| CA2453342A1 (en) | 2003-01-30 |
| CN1231264C (zh) | 2005-12-14 |
| HUP0401046A2 (en) | 2006-04-28 |
| ZA200401161B (en) | 2004-10-22 |
| KR20040018458A (ko) | 2004-03-03 |
| US20040170632A1 (en) | 2004-09-02 |
| HUP0401046A3 (en) | 2006-11-28 |
| PL364599A1 (en) | 2004-12-13 |
| DE10133394A1 (de) | 2003-01-30 |
| RU2004102395A (ru) | 2005-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR039358A1 (es) | Formulacion liquida que comprende cetuximab. | |
| CL2009002199A1 (es) | Anticuerpo que se une especificamente a epitope de cripto; composicion farmaceutica que comprende dicho anticuerpo; uso del anticuerpo para disminuir el crecimiento de un tumor in vitro; metodo para modular el crecimiento de celulas de tumor in vitro en una muestra; anticuerpo humanizado (div. sol. n° 831-2002). | |
| van der Lee et al. | The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers | |
| CO5640082A2 (es) | Compuestos derivados de succinimida heterociclicos fusionados que son moduladores de la funcion del receptor de la hormona nuclear y composiciones farmaceuticas que los contienen | |
| PE20061201A1 (es) | Formulaciones liquidas estabilizadas de polipeptido | |
| PE20190448A1 (es) | Formulacion farmaceutica liquida estable | |
| AR010348A1 (es) | Cetobenzamidas, su utilizacion y composicion farmeceutica que las contienen | |
| MX2019010282A (es) | Formulacion de anticuerpos monoclonales. | |
| PA8583401A1 (es) | Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf) | |
| CO6270340A2 (es) | Formulaciones de anticuerpos anti-cd20 estables a la temperatura y cizalladura | |
| ATE329586T1 (de) | Zusammensetzungen enthaltend carotenoide und deren verwendung zur verhinderung hormon- induzierter nebenwirkungen | |
| AR034389A1 (es) | Monohidrato cristalino de bromuro de tiotropio, procedimiento para su preparacion, su utilización para la preparacion de un medicamento, un medicamento que lo contiene, los hidratos cristalinos del bromuro de tiotropio y un procedimiento para preparacion de estos hidratos cristalinos | |
| UY27961A1 (es) | Compuestos antiinflamatorios de di y trifluoro-triazolo-piridinas | |
| DE60310564D1 (de) | Injizierbare depotformulierung enthaltend iloperidonkrystalle | |
| CL2004000900A1 (es) | Combinacion farmaceutica que comprende (i) un antagonista de la menos un receptor seleccionado de vegfr 1-3, pdgfr alfa y beta, fgfr1-3, egfr, her2, igf1r, hgfr o c-kit, y (ii) al menos un agente quimioterapeutico o terapeutico y su uso en el tratami | |
| CR10493A (es) | Antagonistas de receptor de factor de crecimiento de tipo insulina (igf-ir) como auxiliares para tratamiento de cancer de prostata | |
| UY29182A1 (es) | "derivados de bencenosulfonamidas sustituídas, composiciones que las contienen, procedimientos de preparación y aplicaciones" | |
| CA2454587A1 (en) | Stable lyophilized pharmaceutical formulation of igg antibodies | |
| PA8595001A1 (es) | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) | |
| GB2380675A (en) | Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives | |
| AR034120A1 (es) | Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico | |
| BR112022009563A2 (pt) | Compostos de pirrolotriazina atuando como inibidor de mnk | |
| MX9303123A (es) | Ciclopentano-y-penteno-beta-aminoacidos, procedimiento para su preparacion y medicamentos que los contienen. | |
| UY30175A1 (es) | Combinacion farmacéutica para el tratamiento y/o quimiosensibilizacion de tumores refractarios a drogas anticancerigenas | |
| ES2105285T3 (es) | Nuevos derivados de la adenosina, sus procedimientos de preparacion, composiciones farmaceuticas que los contienen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |